logo/base Created with Sketch.
logo echosens
en-us
chevron Contact
English US version chevron
Change region

FibroScan® Compact 530

The portable non-invasive solution for efficient liver disease management

Powered by LSM by VCTE™ and CAP™ for liver disease management.

chevron chevron
wave

From cart-based to transportable

With its optional roll stand, 15” interactive touchscreen display and durable ergonomic design, FibroScan® Compact 530 is the perfect liver assessment solution for any point-of-care setting.

Adaptive design and ergonomics

LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1. 3,800 peer-reviewed publications support the use of LSM by VCTE™.

CAP™ is unique patented and validated for liver disease management. 1,130 international peer-reviewed publications support the use of CAP™.

 

chevron Discover the clinical evidence

What our users say

quote

As a clinical researcher, I rely heavily on FibroScan® to select the right patient for the right study. Clinical trials in non-alcoholic steatohepatitis typically include patients with specific fibrosis stages. It is thus important to have reliable fibrosis assessment and avoid unnecessary liver biopsies.

Vincent Wong | Hepatologist from Hong Kong

chevron Read all testimonials
chevron chevron

FibroScan® 530 Compact Indications for Use

The FibroScan® Compact 530 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™ ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and
pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should
be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare
professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available
with SmartExam capability.

 

Bibliography

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.

chevron Bibliography

Extend FibroScan® use

chevron Contact us